Altimmune has acquired 2 companies. A total of 1 acquisition came from private equity firms.
Altimmune has acquired in 1 US state, and 2 countries. The Company’s most targeted sectors include healthcare services (50%) and life science (50%).
910 Clopper Road, Suite 201S,
Gaithersburg, Maryland
20878
United States,
(240) 654-1450
www.altimmune.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2015-02-17 |
Immune Targeting Systems Ltd. · Life Science
London, United Kingdom Immune Targeting Systems Ltd. develops synthetic vaccines for mutating viruses. Immune Targeting Systems enabling the T-cell vaccine platform enables it to target highly conserved parts of the virus (“antigens”) and direct a T-cell immune response to those cells in the body infected with one of these difficult viruses. Immune Targeting Systems was founded in 2003 and is based in London, United Kingdom. |
- | Add-on Acquisition | - |
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
